• Pipeline of adult allogeneic mesenchymal stem cells
  
  

Featured Company Pipelines

• Glenmark Pharmaceuticals (India)

• Point Therapeutics (USA)

• Kos Pharmaceuticals (USA)

• Standardized iv product of adult bone marrow stem cells from human donor;
• first product launched for use in bone regeneration;
• lead product for treatment of severe acute graft versus host disease (GvHD);
• clinical studies in Crohn's disease, meniscal repair and myocardial tissue repair

• Small molecule pipeline established within 5 years;
• Focus on metabolic and pulmonary indications;
• Two products in phase II studies;
• PDE-4 inhibitor for asthma partnered in US and Japan

• Focus on dipeptidyl peptidase (DPP) inhibitors;
• First DPP inhibitor in six oncology phase II and III studies;
• DPP-IV inhibitor close to phase I for diabetes;
• DPP inhibitor for use as vaccine adjuvant

(1) Related Product: Dipeptidyl peptidase IV (DPP-IV) Inhibitors

• Continuous annual sales growth rate of > 50 % since 2000 (now US$ 752 mln);
• Core cholesterol franchise with HDL therapies;
• Strong life cycle efforts for proprietary Niaspan (vitamin B niacin);
• New cardiometabolic pipeline projects in early stages;
• Inhaled insulin in phase II;
• Inhalation business for pulmonary diseases.